Christopher Marai
Stock Analyst
(n/a)
# 4,492
Out of 4,497 analysts
18
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
11 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Buy | n/a | $35.55 | - | 2 | May 11, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | n/a | $237.83 | - | 3 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | n/a | $8.37 | - | 1 | Mar 30, 2020 | |
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Buy | n/a | $58.00 | - | 1 | Mar 26, 2020 | |
| BIIB Biogen | Maintains: Buy | n/a | $226.40 | - | 1 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | n/a | $2.20 | - | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | n/a | $145.61 | - | 2 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | n/a | $23.08 | - | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | n/a | $23.58 | - | 2 | Apr 24, 2018 | |
| SLDB Solid Biosciences | Maintains: Buy | n/a | $8.22 | - | 1 | Mar 19, 2018 | |
| CLLS Cellectis | Maintains: Buy | n/a | $2.03 | - | 1 | Sep 6, 2017 |
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: n/a
Current: $35.55
Upside: -
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: n/a
Current: $237.83
Upside: -
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: n/a
Current: $8.37
Upside: -
Corbus Pharmaceuticals Holdings
Mar 26, 2020
Initiates: Buy
Price Target: n/a
Current: $58.00
Upside: -
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: n/a
Current: $226.40
Upside: -
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: n/a
Current: $2.20
Upside: -
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: n/a
Current: $145.61
Upside: -
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: n/a
Current: $23.08
Upside: -
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: n/a
Current: $23.58
Upside: -
Solid Biosciences
Mar 19, 2018
Maintains: Buy
Price Target: n/a
Current: $8.22
Upside: -
Cellectis
Sep 6, 2017
Maintains: Buy
Price Target: n/a
Current: $2.03
Upside: -